TMCnet News
Research and Markets: Israel Pharmaceuticals and Healthcare Report Q4 2008(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:25112008 Dublin - Research and Markets (http://www.researchandmarkets.com/research/f3c373/israel_pharmaceuti) has announced the addition of the "Israel Pharmaceuticals and Healthcare Report Q4 2008" report to their offering. BMI's Israel Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Israel's pharmaceuticals and healthcare industry. Israel's drug market expenditure was estimated at ISL6.2bn (US$1.5bn) in 2007. Over the forecast period (2008-2012), BMI expects the market to grow at an average of 3.3% year-on-year to reach ISL7.2bn (US$2.4bn) in 2012. Growth measured in US dollars should be stronger due to the likelihood of further strengthening of the Israeli shekel against the US dollar. In BMI's updated Business Environment Ratings for Q408, Israel is ranked third out of 15 Middle East and Africa markets surveyed with a score of 54. The country receives the highest score in the region for potential returns, due to the large market size by regional standards and high per capita drug expenditure. Israel's risks to realisation of potential returns are relatively severe. The country's regional isolation creates a moderate degree of political risk. However, the most serious risks are pharmaceutical industryspecific due to a slow approvals process, intellectual property environment that continues to draw criticism from abroad and unclear reimbursement regime. The lack of clear methodology underpinning Israel's reimbursement regime was further highlighted in September 2008 after the Ministry of Health seemingly bowed to patient pressure by adding a screening test performed on couples to detect whether they carry a genetic mutation that would lead to a risk of having children with cystic fibrosis in the basket of health services. The mutation associated with cystic fibrosis is common among Ashkenazi Jews. However, the Ministry of Health had previously resisted its inclusion. In August 2008, Israel was reportedly close to joining the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme (PIC/S), following a successful check of pharmaceutical manufacturing standards in a joint inspection by the Ministry of Health's Institute for Monitoring and Standards and representatives from PIC/S. In the near term, an agreement of mutual recognition will be signed between Israel and the EU, recognising the respective drug manufacturing oversight by regulators. PIC/S membership should further boost Israel's pharmaceutical exports, which continue to underpin the strength of the domestic pharmaceutical industry. According to the Manufacturers' Association of Israel (MAI) pharmaceutical exports reached US$2.22bn in H108, a 43% increase on H107. Such figures suggest exports alone are more than twice the value of domestic drug consumption. Key Topics Covered: - Israel Pharmaceuticals And Healthcare Industry SWOT - Israel Political SWOT - Israel Economics SWOT - Israel Business Environment SWOT - Pharmaceutical Business Environment Ratings - Limits To Potential Returns - Risks To Realisation Of Returns - Israel - Market Summary - Regulatory Regime - Intellectual Property - Shortcomings Of The IP Environment - Counterfeit Drugs - Pricing System - Reimbursement System - Funding For Reimbursement - Industry Trends - Health Status - Healthcare Sector - Healthcare Financing - Retail Sector - Pharmaceutical Industry - Recent Pharmaceutical Industry Developments - Research And Development Sector - Biotechnology - International Research And Development Co-operation - Private Sector - Medical Device Industry - Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Key Growth Factors - Macroeconomic - Prescription Market Forecast - OTC Market Forecast - Generics And Patented Drug Market Forecasts - Import/Export Market Forecast - Other Healthcare Data Forecasts - Key Risks To BMI's Forecast Scenario - Competitive Landscape - BMI Forecast Modelling - How We Generate Our Pharmaceutical Industry Forecasts - Pharmaceutical Business Environment Ratings Methodology Companies Mentioned: - Pfizer - Novartis - Sanofi-Aventis - GlaxoSmithKline - Merck & Co - Indigenous Manufacturer Profiles - Teva Pharmaceutical Industries - Taro; Perrigo (Agis Industries) - Dexcel - Trima - Rekah For more information visit http://www.researchandmarkets.com/research/f3c373/israel_pharmaceuti CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (US) Fax: +353 1 481 1716 (Rest of World) e-mail: [email protected] ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2008 M2 Communications Ltd. |